Details of the Drug

General Information of Drug (ID: DM04LR2)

• Drug Name: Floxuridine
• Synonyms: floxuridine; 50-91-9; 2'-Deoxy-5-fluorouridine; 5-Fluorodeoxyuridine; Fluorodeoxyuridine; Floxuridin; FUDR; Fluoruridine deoxyribose; Deoxyfluorouridine; 5-Fluoro-2'-deoxyuridine; FdUrd; Floxuridinum; Floxiridina; 5FdU; 5-fluoro-1-((2r,4s,5r)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidine-2,4(1h,3h)-dione; 5-Fluoro-2-desoxyuridine; 5 Fluorodeoxyuridine; Floxuridinum [INN-Latin]; FDUR; Floxiridina [INN-Spanish]; beta-5-Fluoro-2'-deoxyuridine; 5-Fluoro-2-deoxyuridine; 5-FdUrd; 5-Fluorouracil deoxyriboside; Sterile fudr (TN); Floxuridine/5-fluorouracil

Indication

Disease Entry	ICD 11	Status	REF
Colorectal cancer	2B91.Z	Approved	[1]
Solid tumour/cancer	2A00-2F9Z	Approved	[2], [3]

• Drug Type: Small molecular drug
• #Ro5 Violations (Lipinski): 0:
  Molecular Weight (mw); 246.19
  Topological Polar Surface Area (xlogp); -1.2
  Rotatable Bond Count (rotbonds); 2
  Hydrogen Bond Donor Count (hbonddonor); 3
  Hydrogen Bond Acceptor Count (hbondacc); 6
• ADMET Property:
  Bioavailability: 90% of drug becomes completely available to its intended biological destination(s) [4]
  Metabolism: The drug is metabolized via the hepatic [5]
• Chemical Identifiers:
  Formula: C9H11FN2O5
  IUPAC Name: 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4-dione
  Canonical SMILES: C1[C@@H]([C@H](O[C@H]1N2C=C(C(=O)NC2=O)F)CO)O
  InChI: InChI=1S/C9H11FN2O5/c10-4-2-12(9(16)11-8(4)15)7-1-5(14)6(3-13)17-7/h2,5-7,13-14H,1,3H2,(H,11,15,16)/t5-,6+,7+/m0/s1
  InChIKey: ODKNJVUHOIMIIZ-RRKCRQDMSA-N
• Cross-matching ID:
  PubChem CID: 5790
  ChEBI ID: CHEBI:60761
  CAS Number: 50-91-9
  DrugBank ID: DB00322
  TTD ID: D0TS1Z
  VARIDT ID: DR00682
  INTEDE ID: DR1754

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Candida Thymidylate synthase (Candi TMP1)	TTU6BFZ	TYSY_CANAL	Inhibitor	[6]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Thymidine phosphorylase (TYMP) Main DME	DE4HCYL	TYPH_HUMAN	Substrate	[7]

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Floxuridine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Roflumilast	DMPGHY8	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Roflumilast.	Asthma [CA23]	[22]
Ofloxacin	DM0VQN3	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Ofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Ciprofloxacin XR	DM2NLS9	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Ciprofloxacin XR.	Bacterial infection [1A00-1C4Z]	[23]
Trovafloxacin	DM6AN32	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Trovafloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Sparfloxacin	DMB4HCT	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Sparfloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Gemifloxacin	DMHT34O	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Gemifloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Norfloxacin	DMIZ6W2	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Norfloxacin.	Bacterial infection [1A00-1C4Z]	[23]
ABT-492	DMJFD2I	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by ABT-492.	Bacterial infection [1A00-1C4Z]	[23]
Levofloxacin	DMS60RB	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Levofloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Lomefloxacin	DMVRH9C	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Lomefloxacin.	Bacterial infection [1A00-1C4Z]	[23]
Grepafloxacin	DMGLX0T	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Grepafloxacin.	Bronchitis [CA20]	[23]
Teriflunomide	DMQ2FKJ	Major	Additive immunosuppressive effects by the combination of Floxuridine and Teriflunomide.	Hyper-lipoproteinaemia [5C80]	[24]
Denosumab	DMNI0KO	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Denosumab.	Low bone mass disorder [FB83]	[25]
Thalidomide	DM70BU5	Major	Additive thrombogenic effects by the combination of Floxuridine and Thalidomide.	Multiple myeloma [2A83]	[26]
Tecfidera	DM2OVDT	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Tecfidera.	Multiple sclerosis [8A40]	[27]
Siponimod	DM2R86O	Major	Additive immunosuppressive effects by the combination of Floxuridine and Siponimod.	Multiple sclerosis [8A40]	[28]
Fingolimod	DM5JVAN	Major	Additive immunosuppressive effects by the combination of Floxuridine and Fingolimod.	Multiple sclerosis [8A40]	[29]
Ocrelizumab	DMEZ2KH	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Ocrelizumab.	Multiple sclerosis [8A40]	[30]
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Floxuridine and Ozanimod.	Multiple sclerosis [8A40]	[22]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Floxuridine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[31]
Gatifloxacin	DMSL679	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Gatifloxacin.	Respiratory infection [CA07-CA4Z]	[23]
Canakinumab	DM8HLO5	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Canakinumab.	Rheumatoid arthritis [FA20]	[32]
Rilonacept	DMGLUQS	Moderate	Additive immunosuppressive effects by the combination of Floxuridine and Rilonacept.	Rheumatoid arthritis [FA20]	[32]
Golimumab	DMHZV7X	Major	Additive immunosuppressive effects by the combination of Floxuridine and Golimumab.	Rheumatoid arthritis [FA20]	[33]
Leflunomide	DMR8ONJ	Major	Additive immunosuppressive effects by the combination of Floxuridine and Leflunomide.	Rheumatoid arthritis [FA20]	[24]
Anthrax vaccine	DM9GSWY	Moderate	Antagonize the effect of Floxuridine when combined with Anthrax vaccine.	Sepsis [1G40-1G41]	[34]
Azathioprine	DMMZSXQ	Moderate	Additive myelosuppressive effects by the combination of Floxuridine and Azathioprine.	Transplant rejection [NE84]	[28]
Cinoxacin	DM4EWNS	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Cinoxacin.	Urinary tract infection [GC08]	[23]
Nalidixic acid	DMRM0JV	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Nalidixic acid.	Urinary tract infection [GC08]	[23]
Enoxacin	DMYTE6L	Minor	Decreased absorption of Floxuridine due to intestinal mucosa variation caused by Enoxacin.	Urinary tract infection [GC08]	[23]
Ganciclovir	DM1MBYQ	Moderate	Additive myelosuppressive effects by the combination of Floxuridine and Ganciclovir.	Virus infection [1A24-1D9Z]	[28]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Floxuridine and Valganciclovir.	Virus infection [1A24-1D9Z]	[28]

References

• [1] Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
• [2] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4801).
• [3] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [4] Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
• [5] FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
• [6] Antisense down-regulation of thymidylate synthase to suppress growth and enhance cytotoxicity of 5-FUdR, 5-FU and Tomudex in HeLa cells. Br J Pharmacol. 1999 Aug;127(8):1777-86.
• [7] Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm. 2008 Sep-Oct;5(5):717-27.
• [8] 5-Fluorouracil pharmacogenomics: still rocking after all these years? Pharmacogenomics. 2011 Feb;12(2):251-65.
• [9] Phase I clinical study of three times a day oral administration of TAS-102 in patients with solid tumors. Cancer Invest. 2008 Oct;26(8):794-9.
• [10] Induction of thymidine phosphorylase in both irradiated and shielded, contralateral human U87MG glioma xenografts: implications for a dual modality treatment using capecitabine and irradiation. Mol Cancer Ther. 2002 Oct;1(12):1139-45.
• [11] Thymidine catabolism as a metabolic strategy for cancer survival. Cell Rep. 2017 May 16;19(7):1313-1321.
• [12] The efficacy of the combination therapy of 5-fluorouracil, cisplatin and leucovorin for hepatocellular carcinoma and its predictable factors. Cancer Chemother Pharmacol. 2004 Apr;53(4):296-304.
• [13] Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines. Int J Cancer. 2003 Feb 20;103(5):587-99.
• [14] Updated clinical information on multitargeted antifolates in lung cancer. Clin Lung Cancer. 2009 Mar;10 Suppl 1:S35-40.
• [15] Trifluorothymidine induces cell death independently of p53. Nucleosides Nucleotides Nucleic Acids. 2008 Jun;27(6):699-703.
• [16] UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res. 2005 Feb 1;11(3):1226-36.
• [17] DNA damage and homologous recombination signaling induced by thymidylate deprivation. Biochem Pharmacol. 2008 Oct 15;76(8):987-96.
• [18] Decreased levels of UMP kinase as a mechanism of fluoropyrimidine resistance. Mol Cancer Ther. 2009 May;8(5):1037-44.
• [19] Antifungal agents: mode of action in yeast cells. Rev Esp Quimioter. 2006 Jun;19(2):130-9.
• [20] A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq (nolatrexed dihydrochloride) given by 10-day oral administration. Br J Cancer. 1999 Feb;79(5-6):915-20.
• [21] Cooperative inhibition of human thymidylate synthase by mixtures of active site binding and allosteric inhibitors. Biochemistry. 2007 Mar 13;46(10):2823-30.
• [22] Cerner Multum, Inc. "UK Summary of Product Characteristics.".
• [23] Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
• [24] Product Information. Arava (leflunomide). Hoechst Marion-Roussel Inc, Kansas City, MO.
• [25] Product Information. Prolia (denosumab). Amgen USA, Thousand Oaks, CA.
• [26] Bennett CL, Nebeker JR, Samore MH, et al "The Research on Adverse Drug Events and Reports (RADAR) project." JAMA 293 (2005): 2131-40. [PMID: 15870417]
• [27] Product Information. Vumerity (diroximel fumarate). Alkermes, Inc, Cambridge, MA.
• [28] Cerner Multum, Inc. "Australian Product Information.".
• [29] Product Information. Gilenya (fingolimod). Novartis Pharmaceuticals, East Hanover, NJ.
• [30] Product Information. Ocrevus (ocrelizumab). Genentech, South San Francisco, CA.
• [31] Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
• [32] Product Information. Arcalyst (rilonacept). Regeneron Pharmaceuticals Inc, Tarrytown, NY.
• [33] Product Information. Cimzia (certolizumab). UCB Pharma Inc, Smyrna, GA.
• [34] CDC. Centers for Disease Control and Prevention/ "Recommendations of the advisory committtee on immunization practices (ACIP): use of vaccines and immune globulins in persons with altered immunocompetence." MMWR Morb Mortal Wkly Rep 42(RR-04) (1993): 1-18. [PMID: 20300058]